Hepatitis C virus: The growing challenge

British Medical Bulletin

Volumn 89, Issue 1, 2009, Pages 153-167

  Thomson, Brian J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Hepatitis C virus; Models of care; Pathogenesis; Treatment

Indexed keywords

5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ACH 806; ANTIVIRUS AGENT; CILUPREVIR; GS 9132; MONTIRELIN; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE; TELAPREVIR; UNCLASSIFIED DRUG; VALOPICITABINE; VIRUS PROTEIN; VIRUS RNA;

ANTIVIRAL THERAPY; CESAREAN SECTION; DEVELOPING COUNTRY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROSEXUALITY; HUMAN; INCIDENCE; INDUSTRIALIZATION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MALE HOMOSEXUAL; MORTALITY; NONHUMAN; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; SEXUALITY; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; DRUG EFFECT; PHYSIOLOGY; SUBSTANCE ABUSE;

HEPACIVIRUS; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; VIRUS REPLICATION;

EID: 70349770304     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldp003     Document Type: Review

References (43)

1. Sharma P, Lok A (2006) Viral hepatitis and liver transplantation. Semin Liver Dis, 26, 285-297
2. Wasley A, Alter MJ (2000) Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis, 20, 1-16
3. Health Protection Agency (2008) Hepatitis C in England: An Update. Annual Report. London: Health Protection Agency
4. Sweeting MJ, De Angelis D, Brant L, Harris HE, Mann AG, Ramsay ME (2007) The burden of hepatitis C in England. J Viral Hepat, 14, 570-576
5. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB (2007) Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat, 14, 107-115
6. Dubuisson J (2007). Hepatitis C virus proteins. World J Gastroenterol, 13, 2406-2415
7. Dubuisson J, Helle F, Cocquerel L (2008) Early steps of the hepatitis C virus life cycle. Cell Microbiol, 10, 821-827
8. Dreux M, Peitschmann T, Granler M et al. (2006) High density lipoprotein inhibits hepatitis C virus-neutralising antibodies by stimulating cell entry via activation of the scavenger receptor B 1. J Biol Chem, 281, 18285-18295
9. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S (2000) Hepatitis C virus kinetics. Antivir Ther, 5, 85-90
10. Bartenschlager R, Lohmann V (2001) Novel cell culture systems for the hepatitis C virus. Antivir Res, 52, 1-17
11. Wakita T, Pietschmann T, Kato T et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med, 11, 791-796
12. Zhong J, Gastaminza P, Cheng G et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA, 102, 9294-9299
13. Lindenbach BD, Evans MJ, Syder AJ et al. (2005) Complete replication of hepatitis C virus in cell culture. Science, 309, 623-626
14. Pietschmann T, Kaul A, Koutsoudakis G et al. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA, 103, 7408-7413
15. Scheel TKH, Gottwein JM, Jensen TB et al. (2008) Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralisation. Proc Natl Acad Sci USA, 105, 997-1902
16. Owsianka AM, Tarr AW, Keck Z-Y et al. (2008) Broadly neutralising human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol, 89, 653-659
17. Molina S, Castet V, Fournier-Wirth C et al. (2007) The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol, 46, 411-419
18. Molina S, Castet V, Pichard-Garcia L et al. (2008) Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol, 82, 569-574
19. Frank C, Mohamed MK, Strickland GT et al. (2000) The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet, 355, 887-891
20. Vandelli C, Renzo F, Romano L et al. (2005) Lack of evidence of sexual transmission of hepatitis C among monomagous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol, 99, 855-859
21. Danta M, Brown D, Bhagani S et al. (2007) Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS, 21, 983-991
22. Pembrey L, Newell ML, Tovo PA, EPHN Collaborators (2005) The management of HCV infected pregnant women and their children European paediatric HCV network. BJOG, 43, 515-525
23. Lawson A, Hagan S, Rye K et al. (2007) The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol, 47, 37-45
24. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 127, S35-S50
25. El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 127, S27-S34
26. Thomson BJ, Kwong G, Ratib S et al. (2008) Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat, 15, 271-278
27. Dudley T, O'Donnell K, Haydon G, Mutimer D (2006) Disappointing results of combination therapy for HCV? Gut, 55, 1362-1363
28. Jensen DM, Morgan TR, Marcellin P et al. (2006) Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon a-2a (40 kDa)/ribavirin therapy. Hepatology, 43, 954-960
29. Mangia A, Santoro R, Minerva N et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med, 352, 2609-2617
30. Neal KR, Trent Hepatitis C Study Group, Ramsay S, Thomson BJ, Irving WL (2007) Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut, 56, 1098-1104
31. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ (2006) Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community based linkage study. Lancet, 368, 938-945
32. Micallef JM, Kaldor JM, Dore GJ et al. (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat, 13, 34-41
33. Jaeckel E, Cornberg M, Wedemeyer H et al. (2001) Treatment of acute hepatitis C with inter-feron alfa-2b. N Eng J Med, 345, 1452-1457
34. Sypsa V, Touloumi G, Tassopousos NC et al. (2004) Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends in cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat, 11, 366-374
35. Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology, 39, 1147-1171
36. NICE Technology Assessment number 106; TA106. www.nice.org.uk/ TA106guidance
37. Irving WL, Smith S, Cater R et al. (2006) Clinical pathways for patients with newly diagnosed hepatitis C-what actually happens. J Viral Hepat, 4, 264-271
38. Jeffrey GP, MacQuillan G, Chua F et al. (2007) Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology, 45, 111-117
39. Grebely J, Raffa JD, Meagher C et al. (2007) Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol, 22, 1519-1525
40. Moriishi K, Matsuura Y (2007) Evaluation systems for anti-HCV drugs. Adv Drug Deliv Rev, 59, 1213-1221
41. Hao W, Duggal R (2009) High-throughput screening of HCV RNA replication inhibitors by means of a reporter replicon system. Meth Mol Biol, 510, 243-250
42. Qi X, Bae A, Liu S et al. (2009) Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res, 81, 166-173
43. Lawitz E, Rodriguez-Torres M, Muir AJ et al. (2008) Antiviral effects and safety of telapre-vir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol, 49, 163-169